Prescription drug · ANDA
lamivudine (Lamivudine oral) NDC 62135-706
Lamivudine 10 mg/mL · Solution · Oral · Chartwell RX, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62135-706-24 | 6213507062462135070624 | 2 TRAY in 1 BOX (62135-706-24) / 10 CUP in 1 TRAY / 30 mL in 1 CUP (62135-706-30)Marketed from Mar 6, 2025 | |
| 62135-706-37 | 6213507063762135070637 | 240 mL in 1 BOTTLE, PLASTIC (62135-706-37)Marketed from Jul 20, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- lamivudine
- Generic name (nonproprietary)
- lamivudine oral
- Active ingredients
- Lamivudine — 10 mg/mL
- Dosage form
- Solution
- Route
- Oral
- Labeler
- Chartwell RX, LLCNDC labeler code 62135
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 203564
- Marketing start
- Listing expires
- Other FDA classes
- Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
- Identifiers
- Product ID 62135-706_472f29d3-cf7e-0a76-e063-6294a90a9e7aSPL ID 472f29d3-cf7e-0a76-e063-6294a90a9e7aSPL set ID ef9977cb-ec91-46d7-b769-d26decfd6fe7RxCUI 199148UNII 2T8Q726O95UPC 0362135706371
- Pharmacologic class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462135070624followed by a unit qualifier and the quantityPackage 62135-0706-24. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Lamivudine oral solution, USP is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. Lamivudine oral solution, USP is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 62135-706
- What is NDC 62135-706?
- 62135-706 is the product NDC for lamivudine (lamivudine oral), Lamivudine 10 mg/mL solution, listed with the FDA by Chartwell RX, LLC. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- lamivudine (Lamivudine oral).
- What is the active ingredient?
- Lamivudine.
- Who is the labeler?
- Chartwell RX, LLC, NDC labeler code 62135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for lamivudine?
- 23 other product NDCs are listed under this name. See all lamivudine NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other lamivudine products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Lamivudine | Lamivudine 150 mg/1 | Tablet, Film coatedOral | Coupler LLC | 67046-1459 | 67046-1459-03 |
| Lamivudine | Lamivudine 150 mg/1 | Tablet, Film coatedOral | American Health Packaging | 60687-720 | 60687-0720-21 |
| Lamivudine | Lamivudine 150 mg/1 | Tablet, Film coatedOral | Macleods Pharmaceuticals Limited | 33342-001 | 33342-0001-09 |
| Lamivudine | Lamivudine 300 mg/1 | Tablet, Film coatedOral | Macleods Pharmaceuticals Limited | 33342-002 | 33342-0002-07 |
| lamivudine | Lamivudine 100 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-001 | 31722-0001-0231722-0001-60 |
| Lamivudine | Lamivudine 150 mg/1 | Tablet, Film coatedOral | Strides Pharma Science Limited | 64380-710 | 64380-0710-03 |
| Lamivudine | Lamivudine 300 mg/1 | Tablet, Film coatedOral | Strides Pharma Science Limited | 64380-711 | 64380-0711-04 |
| Lamivudine | Lamivudine 150 mg/1 | TabletOral | Ingenus Pharmaceuticals, LLC | 50742-623 | 50742-0623-60 |
| Lamivudine | Lamivudine 300 mg/1 | TabletOral | Ingenus Pharmaceuticals, LLC | 50742-624 | 50742-0624-60 |
| Lamivudine | Lamivudine 10 mg/mL | SolutionOral | Rising Pharma Holdings, Inc. | 57237-274 | 57237-0274-24 |
Other NDCs under ANDA 203564
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| lamivudinelamivudine oral | Lamivudine 10 mg/mL | SolutionOral | Chartwell Govermental & Specialty RX, LLC. | 68999-706 |